On November 13, Gelonghui reported that Zhuhai Rundu Pharmaceutical (002923.SZ) announced that the company recently received the "Notification of Approval for Supplementary Application for Pharmaceutical" issued by the National Medical Products Administration. The pharmaceutical name is Irbesartan tablets, and the National Medical Products Administration approved an additional specification of 75mg, issued a pharmaceutical approval number, and the new specification product will be packaged in solid oral high-density polyethylene bottles. Irbesartan tablets are indicated for the treatment of primary hypertension and the treatment of type 2 diabetic nephropathy with hypertension.
润都股份(002923.SZ)：厄贝沙坦片获得药品补充申请批准通知书
Zhuhai Rundu Pharmaceutical (002923.SZ): The approval notice for the supplementary application of Irbesartan tablets was received.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney